Need Assistance? Call us today! 714-296-5151
Low-sodium oxybate is still indicated for idiopathic hypersomnia, but researchers are looking at many factors when prescribing treatment. Low-sodium oxybate was the first idiopathic hypersomnia treatment to receive approval by the FDA. However, many off-label treatments continue to be used.
Researchers concluded that adjunct nonpharmacologic therapies, including good sleep hygiene, patient education and counseling, and use of support groups—should be recognized and recommended when appropriate. Clinical Considerations in the Treatment of Idiopathic Hypersomnia (on PubMed) describes optimal treatment strategies that take into account patient-specific factors.
The article "Clinical Considerations in the Treatment of Idiopathic Hypersomnia," published in Sleep Medicine journal, discusses various aspects of managing this sleep disorder. Idiopathic hypersomnia (IH) is characterized by excessive daytime sleepiness despite adequate or prolonged nighttime sleep. The pathogenesis of IH remains unclear, with no consistent abnormalities identified in key neurotransmitters involved in wakefulness. Genetic predisposition is suggested due to frequent family histories of hypersomnia-related symptoms.
Diagnosis is based on the International Classification of Sleep Disorders, Third Edition (ICSD-3) criteria, which include excessive daytime sleepiness for at least three months and exclusion of other causes. Sleep inertia, although not a diagnostic criterion, is a common symptom.
Treatment primarily involves off-label use of wake-promoting agents and stimulants, as there are no FDA-approved treatments specifically for IH outside of the United States. Xywav is the only FDA-approved medication for adult patients with IH, shown to significantly improve symptoms.
The article highlights the need for more research into IH's pathophysiology to develop targeted therapies and reliable biomarkers. Additionally, better diagnostic protocols are needed to distinguish IH from other sleep disorders, particularly narcolepsy type 2, which shares overlapping symptoms. This research is critical for improving diagnostic accuracy and treatment efficacy for IH patients.
Further studies are also recommended to explore treatment options for pediatric patients and to address the unmet needs of IH patients globally. Overall, a combination of clinical judgment and appropriate diagnostic testing is essential for effective management of this debilitating disorder.
Source: ScienceDirect